Non‐small cell lung cancer (NSCLC) treatment has advanced greatly over the past two decades due to treatments targeting driver alterations in genes including anaplastic lymphoma kinase (ALK), B‐Raf (BRAF), and epidermal growth factor receptor (EGFR).1 The gene discussed is BRAF; the disease is non-small cell lung carcinoma.